推薦產品
![[去氨基-Cys1, D-Arg8]-加压素 乙酸盐 水合物 ≥95% (HPLC)](/deepweb/assets/sigmaaldrich/product/structures/215/222/82da3633-80ea-463d-8b55-e99fb8e442e0/640/82da3633-80ea-463d-8b55-e99fb8e442e0.png)
![[Arg8]-Vasopressin acetate salt ≥95% (HPLC)](/deepweb/assets/sigmaaldrich/product/structures/282/717/a4c16d4f-e168-4d84-a0e3-59de3e06251e/640/a4c16d4f-e168-4d84-a0e3-59de3e06251e.png)
化驗
≥98% (HPLC)
形狀
powder
顏色
white to tan
溶解度
DMSO: ≥15 mg/mL
起源
Sanofi Aventis
儲存溫度
2-8°C
SMILES 字串
Cc1ccccc1C(=O)Nc2ccc(c(C)c2)C(=O)N3CCCC(O)c4cc(Cl)ccc34
InChI
1S/C26H25ClN2O3/c1-16-6-3-4-7-20(16)25(31)28-19-10-11-21(17(2)14-19)26(32)29-13-5-8-24(30)22-15-18(27)9-12-23(22)29/h3-4,6-7,9-12,14-15,24,30H,5,8,13H2,1-2H3,(H,28,31)
InChI 密鑰
GYHCTFXIZSNGJT-UHFFFAOYSA-N
基因資訊
human ... AVPR2(554)
應用
Tolvaptan has been used as a V2-selective antagonist for studying its effect on hypertension in mice[1].
生化／生理作用
Tolvaptan (OPC 41061) is a potent, orally active non-peptide vasopressin V2 selective antagonist. IC50 = 3 nM at the rat V2 receptor; 29 times more selective for the V2 than for V1a. Tolvaptan has also been shown to inhibit the development of polycystic kidney disease in several animal models.
Tolvaptan is a potent, orally active non-peptide vasopressin V2 receptor antagonist.
特點和優勢
This compound was developed by Sanofi Aventis. To browse the list of other pharma-developed compounds and Approved Drugs/Drug Candidates, click here.
準備報告
Tolvaptan is soluble in DMSO at a concentration that is greater than or equal to 15 mg/ml.
儲存類別代碼
11 - Combustible Solids
水污染物質分類（WGK）
WGK 3
閃點（°F）
Not applicable
閃點（°C）
Not applicable
從最近期的版本中選擇一個：
分析證明 (COA)
Lot/Batch Number
客戶也查看了
[Adverse effects of cardiovascular agents in Japan--update 2012].
Yayoi Tetsuou Tsukada
Nihon rinsho. Japanese journal of clinical medicine, 70 Suppl 6, 239-244 (2012-11-20)
Mohamed El-Shabrawy et al.
Pharmacology research & perspectives, 8(5), e00659-e00659 (2020-10-01)
Cyclophosphamide (CP) is a chemotherapeutic agent which is extensively used in the treatment of multiple neoplastic and nonneoplastic diseases like breast cancer, lymphomas, systemic lupus erythematosus, and multiple sclerosis. Dose-limiting side effects, mainly nephrotoxicity is a major problem hindering its
Christine Yu et al.
Experimental and clinical transplantation : official journal of the Middle East Society for Organ Transplantation, 11(1), 3-11 (2013-02-08)
Hyponatremia has long been associated with worsened clinical outcomes in patients with cirrhosis and those awaiting liver transplant. However, in the last several years, new modalities of therapy, particularly aquaretics known as "vaptans," and comprehensive prognostic models have been increasingly
Yuya Matsue et al.
Journal of cardiology, 61(2), 169-174 (2012-11-20)
Although tolvaptan is a recently approved drug for heart failure and causes aquaresis without affecting renal function, its clinical efficacy for patients with acute decompensated heart failure (ADHF) is yet to be elucidated. We conducted a prospective observational study in
Kiyotaka Watanabe et al.
Journal of cardiology, 60(6), 462-469 (2012-10-17)
We evaluated the short-term effects of low-dose tolvaptan treatment on hemodynamic parameters in patients with chronic heart failure (HF). We studied 22 patients (69 ± 10 years) with chronic HF and excess fluid retention despite receiving appropriate medical therapy, including
Active Filters
我們的科學家團隊在所有研究領域都有豐富的經驗，包括生命科學、材料科學、化學合成、色譜、分析等.
聯絡技術服務
